

A Case of Pancytopenia with Many Possible Causes: How Do You Tell Which is the Right One?

<u>Priscila Diaz</u>, Mariana Abreu Vieira, António Carneiro, Natália Fernandes Department of Internal Medicine, Cascais Hospital, Cascais, Portugal.

Doi: 10.12890/2019_001012 - European Journal of Case Reports in Internal Medicine - © EFIM 2019

Received: 05/12/2018 Accepted: 17/12/2018 Published: 30/01/2019

How to cite this article: Diaz P, Abreu Vieira M, Carneiro A, Fernandes N. A case of pancytopenia with many possibile causes: how do you tell which is the right one? *EJCRIM* 2019;6: doi:10.12890/2019_001012.

Conflicts of Interests: The Authors declare that there are no competing interests. **This article is licensed under a Commons Attribution Non-Commercial 4.0 License**

ABSTRACT

Systemic lupus erythematosus (SLE) often presents with cytopenia(s); however, pancytopenia is found less commonly, requiring the consideration of possible aetiologies other than the primary disease. The authors describe the case of a female patient with a recent diagnosis of SLE admitted through the Emergency Department with fever of unknown origin and severe pancytopenia. She was medicated with prednisolone, hydroxychloroquine, azathioprine, amlodipine and sildenafil. Extensive investigation suggested azathioprine-induced myelotoxicity. However, the patient was found to have a concomitant cytomegalovirus (CMV) infection, with oral lesions, positive CMV viral load as well as the previously described haematological findings. Pancytopenia is always a diagnostic challenge, with drug-induced myelotoxicity, especially secondary to azathioprine, being a rare aetiology. This report reiterates the importance of the differential diagnosis of pancytopenia, especially in immunosuppressed patients with increased risk for opportunistic infections.

LEARNING POINTS

- The possibility of multiple aetiologies for pancytopenia in the same patient should be considered.
- Azathioprine-induced myelotoxicity is dose-dependent and pancytopenia is a rare form of presentation.
- Opportunistic infections should always be considered as a cause of cytopenias when immunosuppression is present.

KEYWORDS

Pancytopenia, systemic lupus erythematosus, azathioprine, cytomegalovirus

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease affecting multiple organs and systems. Cytopenias are common, however pancytopenia is found less frequently, requiring the consideration of possible aetiologies other than the primary disease. Active disease and immunosuppressive treatment should be the first possible causes to be considered^[1].

CASE DESCRIPTION

The authors report the case of a 40-year-old female patient, with Hashimoto hypothyroidism and recently diagnosed SLE, medicated with prednisolone 60 mg/daily, hydroxychloroquine 400 mg/daily and azathioprine 100 mg/daily. She was admitted through the Emergency Department reporting a 4-day course of fever (39°C), odynophagia and multiple and painful oral ulcers. On examination, she was febrile (38°C) with extensive leucoplakia.



The patient was found to have severe pancytopenia (normocytic normochromic anaemia with a haemoglobin of 6.3 g/dl, leukopenia 350×10^6 /l with neutropenia 120×10^6 /l, and thrombocytopaenia 110×10^9 /l) and mildly elevated inflammatory markers (C-reactive protein 5.96 mg/dl). Blood smear showed moderate anisopoikilocytosis with platelet anisocytosis.

The patient was prescribed piperacillin/tazobactam and fluconazole as a diagnosis of pancytopenia with neutropenic fever syndrome and oropharyngeal candidiasis was made. Additionally, azathioprine was suspended, due to potential drug-induced myelotoxicity. After resolution of the oral leucoplakia, multiple ulcers became evident, suggestive of viral or pemphigoid aetiology (*Figs.* 1–4).



No clinical or biochemical signs of active SLE were found, with normal complement and anti-dsDNA antibody levels. Vitamin B12 and folic acid levels were within the normal range. The patient was found to have positive IgM and IgG cytomegalovirus (CMV) antibodies, with a viral load of 2,800 copies/ml; testing was negative for other viruses, such as EBV, parvovirus, herpes simplex 1/2 and HIV. Blood, urine and bone marrow cultures were negative. Bone marrow aspiration was compatible with drug-induced agranulocytosis. Thiopurine methyltransferase (TPMT) was 11.9 U/ml (normal >19 U/ml).

As previously stated, azathioprine was suspended, and the patient was prescribed valganciclovir 900 mg every 12 hours, with complete resolution of the oral ulcers and haematological improvement (*Table 1*).

Complete Blood Count	Day 0	Day 6	Day 9	Day 14	Day 18
Haemoglobin (g/dl)	6.3	7.7	8.0	8.9	9.0
White blood cells (×10 ⁹ /l)	0.35	0.42	0.67	1.59	2.12
Neutrophils (×10°/l)	0.12	0.05	0.14	0.85	1.37
Lymphocytes (×10 ⁹ /l)	0.21	0.35	0.25	0.57	0.69
Platelets (×10°/l)	110	20	18	72	218

Table 1. Cytopenia progression throughout hospitalisation



DISCUSSION

Pancytopenia, defined as a reduction in all three peripheral blood lineages, can result from bone marrow infiltration, aplasia or increased cell destruction or sequestration. Disease severity is dependent on aetiology (for example, acute leukaemia) and clinical impact (for example, symptomatic anaemia or febrile neutropenia). It often represents a diagnostic challenge, mainly because patients are increasingly complex, often having multiple potential confounding (and contributing) comorbidities and medications.

In SLE patients, pancytopenia is often related to other causes, apart from the autoimmune condition, for example haemophagocytic lymphohistiocytosis, macrophage activation syndrome, septic or drug-induced myelotoxicity and haematological malignancies.

Azathioprine is often used as a steroid-sparing drug, interfering with purine and protein synthesis. TPMT is an important enzyme involved in azathioprine metabolization, with low blood activity being associated with increased risk for drug-related toxicity^[2]. Azathioprine-induced myelotoxicity is dose-dependent and the most common effect is leukopenia (5–25%)^[3]; pancytopenia is rare. SLE patients seem to be more susceptible to these adverse events^[4], which tend to manifest in the first 3 weeks of treatment, and last for 3 weeks after drug suspension. Some patients may require colony-stimulating factors^[5].

An additional remark regarding opportunistic infections and their contribution to myelosuppression is in order. CMV can remain latent after a primary infection and reactivate when allowed, especially in permissive immunological states, such as drug-induced immunosuppression. CMV infection can range from mild flu-like symptoms, to cytopenias, to severe acute (even life-threatening) syndromes, such as haemophagocytic lymphohistiocytosis. Recommended treatment is intravenous ganciclovir or oral valganciclovir.

CONCLUSION

This case report is extremely relevant since it illustrates the complexity of the differential diagnosis of pancytopenia, and how this disorder can result from a combination of multiple aetiologies (comorbidities, medication, acute infections) rather than just one: this patient had an autoimmune disease which often presents with cytopenias, she was medicated with a potentially myelotoxic drug and she had signs of ongoing CMV infection.

REFERENCES

- 1. Levine AB, Erkan D. Clinical assessment and management of cytopenias in lupus patients. Curr Rheumatol Rep 2011;13:291–299.
- 2. Neto MP, Alves AN, Fortina A, Burattini M, Sumita NM, Srougi M, et al. Therapeutic drug monitoring of azathioprine: a review. Bras Patol Med Lab 2008;44:161–167.
- 3. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine an enzyme deficiency caused by a common genetic polymorphism. J Royal Soc Med 1992;85:752–756.

Yeter KC, Afkhami M, Brynes RK, et al. Aplastic anemia secondary to azathioprine in systemic lupus erythematosus: report of a case with normal thiopurine S-methyltransferase enzyme activity and review of the literature. Lupus 2013;22:1526–1528.

Jensen CH, Tiu J, Catalanotti JS. Azathioprine-induced pancytopenia with normal TPMT activity presenting with HSV oral ulcers. BMJ Case Rep 2018; doi:10.1136/bcr-2018-225209.